SCHEMBL427563

SCHEMBL427563

COc1ccc(-c2cn(C(=O)N3COCC3(C)C)cn2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KDM4E B2RXH2 3/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
CD274 Q9NZQ7 1/20 0.38
CACNA1H O95180 3/20 0.37
CNR2 P34972 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427176 0.92 CACNA1H (0.37) ALDH1A1KDM4ELMNACACNA1HCNR2
SCHEMBL427475 0.91 CNR2 (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL426001 0.88 CNR2 (0.37) ALDH1A1LMNACNR2L3MBTL1HTT
SCHEMBL427043 0.87 FYN (0.39) GAAJAK2
SCHEMBL425981 0.87 MIF (0.36) KDM4ELMNACNR2
SCHEMBL425883 0.85 KDM1A (0.33) ALDH1A1SMN1; SMN2KDM4EGLAGAA
SCHEMBL427620 0.84 KDM4E (0.38) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL425709 0.82 KDM4E (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL427956 0.82 TP53 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL427535 0.81 CNR2 (0.35) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 ALDH1A1 294/4885NPC1 446/4885RAB9A 2266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.